Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
Holders of 5% or more of CLDX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Celldex Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Wellington Management Group LLP | 13G/A | 11.10%7.39M shares | +3.20 ppfrom 7.90% | May 12, 20253 filings | Nov 7, 2025 | SEC |
| Kynam Capital Management, LP | 13G/A | 9.79%6.50M shares | +2.16 ppfrom 7.63% | Feb 14, 20252 filings | May 15, 2025 | SEC |
| FMR LLC | 13G/A | 7.30%4.86M shares | – | Feb 12, 20251 filing | Feb 12, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.30%4.82M shares | −1.00 ppfrom 8.30% | Feb 5, 20252 filings | Apr 17, 2025 | SEC |
| Bellevue Group AG | 13G | 5.40%3.62M shares | New | Nov 14, 20251 filing | Nov 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
17 Schedule 13D and 13G filings on Celldex Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20265:16 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Mar 10, 20266:41 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 2.60%1.76M shares | −4.10 ppfrom 6.70%Below 5% | Dec 31, 2025 | SEC |
| Nov 14, 20257:58 PM ET | Bellevue Group AGand 1 other | 13G | 5.40%3.62M shares | New | Aug 18, 2025 | SEC |
| Nov 14, 20255:08 PM ET | Commodore Capital LPand 1 other | 13G/A | 4.60%3.03M shares | −0.40 ppfrom 5.00%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 202512:19 PM ET | Price T Rowe Associates Inc | 13G/A | 3.60%2.38M shares | −1.80 ppfrom 5.40%Below 5% | Sep 30, 2025 | SEC |
| Nov 7, 20258:18 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 11.10%7.39M shares | +3.20 ppfrom 7.90% | Oct 31, 2025 | SEC |
| Aug 14, 20252:59 PM ET | Eventide Asset Management, LLCand 2 others | 13G/A | 2.00%1.36M shares | –Below 5% | Jun 30, 2025 | SEC |
| Aug 12, 202510:34 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 7.90%5.23M shares | −4.70 ppfrom 12.60% | Jun 30, 2025 | SEC |
| Jul 10, 20254:10 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 6.70%4.46M shares | New | Jul 2, 2025 | SEC |
| May 15, 202511:48 AM ET | Kynam Capital Management, LPand 2 others | 13G/A | 9.79%6.50M shares | +2.16 ppfrom 7.63% | Mar 31, 2025 | SEC |
| May 12, 202510:44 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 12.60%8.35M shares | – | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 7.30%4.82M shares | −1.00 ppfrom 8.30% | Mar 31, 2025 | SEC |
| Apr 10, 20254:05 PM ET | Commodore Capital LPand 1 other | 13G | 5.00%3.35M shares | New | Apr 3, 2025 | SEC |
| Feb 14, 20255:16 PM ET | Kynam Capital Management, LPand 2 others | 13G/A | 7.63%5.06M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20259:44 AM ET | Price T Rowe Associates Inc | 13G | 5.40%3.56M shares | New | Dec 31, 2024 | SEC |
| Feb 12, 20259:28 AM ET | FMR LLCand 1 other | 13G/A | 7.30%4.86M shares | – | Dec 31, 2024 | SEC |
| Feb 5, 20251:23 PM ET | BlackRock, Inc. | 13G/A | 8.30%5.48M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Celldex Therapeutics, Inc. shares.
No Form 144 notices for Celldex Therapeutics, Inc. are on file.